Cell and gene therapy sector remains strong despite challenges: ARM CEO The cell and gene therapy sector is “quite strong” despite the regulatory, investment, and manufacturing challenges facing the industry, according to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM). Lambert spoke with ScienceBoard.net about developments in the industry.Read More
Machine learning model opens door to real-time detection of cell therapy contamination Researchers at the Massachusetts Institute of Technology’s Singapore site have developed a new way to detect adventitious microbial contamination in mesenchymal stromal cell cultures. By using machine learning to predict if a culture is contaminated in near real-time, the approach could enable testing to take place during the production of cell therapy products.Read More
Mammoth Biosciences looks to build next-generation CRISPR toolbox This month marks the 10th anniversary of the development of CRISPR as a genome-editing tool. While the technology is fairly new, it has made major strides over the past decade, said Mammoth Biosciences co-founder and CEO Trevor Martin in an interview with ScienceBoard.net.Read More
Illumina brings whole-genome sequencing to German hospital Illumina has signed an agreement with Hannover Medical School in Germany to assess the use of rapid whole-genome sequencing (rWGS) in critically ill children suspected of having a genetic or rare disease.Read More
Meeting on the Med opens with new data and eyes on the money BARCELONA, SPAIN -- The Cell & Gene Meeting on the Med conference kicked off on April 20 as speakers assessed the current state of the cell and gene therapy sector and explored payment strategies for advanced therapies across the European Union.Read More
Nivolumab/chemo combo will change lung cancer care A new study that pairs neoadjuvant nivolumab with chemotherapy for patients with nonsmall cell lung cancer has the potential to revolutionize treatment, according to one expert. The research was presented April 11 at the American Association for Cancer Research 2022 meeting and published simultaneously in the New England Journal of Medicine.Read More
CAR T-cells show preliminary efficacy, safety as solid-tumor treatment Researchers presented phase I/II preliminary clinical trial data demonstrating the safety and efficacy of a new CAR T-cell therapy that can be used as either a monotherapy or a combination therapy to treat Claudin 6-positive solid tumors. The findings were presented at the American Association for Cancer Research Annual Meeting 2022 in New Orleans.Read More